<DOC>
	<DOCNO>NCT01157858</DOCNO>
	<brief_summary>The aim study reduce polycystic liver volume treat octreotide , whether combine everolimus ; ass whether combination therapy everolimus octreotide give big reduction polycystic liver volume octreotide monotherapy .</brief_summary>
	<brief_title>Everolimus LongActing Octreotide Trial Polycystic Livers</brief_title>
	<detailed_description>This single center randomize , open-label , parallel study compare safety efficacy everolimus-octreotide LAR treatment monotherapy octreotide LAR adult symptomatic patient polycystic liver polycystic liver disease ( PCLD ) . We aim include 44 patient affected polycystic liver either due PCLD , 22 patient combination group 22 patient mono therapy group.The duration trial 52 week . The treatment 48 week last control visit take place four week treatment .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cysts</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>18 &lt; age ≤ 70 year Polycystic liver disease ( PCLD ) , define ≥ 20 liver cyst Total liver volume must least 2500 mL Symptomatic define ECOGPS ≥ 1 ( see fig 3.1 ) 38 , least three ten PCLD symptom : Abdominal pain Abdominal distension Abdominal fullness Dyspnea Early satiety Back pain Nausea/vomiting Anorexia Weight loss Jaundice Informed consent , patient willing able comply study drug regimen study requirement ADPKD patient Use oral anticonceptives estrogen supplementation Females pregnant breastfeeding patient reproductive potential employ effective method birth control . Women childbearing potential must negative serum pregnancy test within 48 hour prior administration study medication . Intervention ( aspiration surgical intervention ) within three month baseline Treatment somatostatin analogue within three month baseline Patients kidney transplant History evidence chronic pulmonary disease associate functional limitation History severe cardiac disease ( eg , NYHA Functional Class III IV , myocardial infarction within 6 month , ventricular tachyarrhythmias require ongoing treatment , unstable angina significant cardiovascular disease ) . In addition , patient document presumed coronary artery disease cerebrovascular disease enrol . History evidence severe illness condition would make patient , opinion investigator , unsuitable study Symptomatic gallstone ( octreotide decrease gall bladder volume ) Hypercholesterolemia ( fast cholesterol &gt; 8 mmol/l ) hypertriglyceridaemia ( &gt; 5 mmol/l ) control lipid lowering therapy Granulocytopenia ( white blood cell &lt; 3,000/mm3 ) thrombocytopenia ( platelet &lt; 100,000/mm3 ) Infection hepatitis B , hepatitis C , HIV , TBC ( medical history ) Mental illness interfere patient ability comply protocol Drug alcohol abuse within one year baseline Comedication strong inhibitor CYP3A4 Pgp like voriconazole , ketoconazole , diltiazem , verapamil , erythromycin strong CYP3A4 Pgp inductor like rifampicin Known hypersensitivity everolimus one excipients Enrolment another clinical trial investigational agent participate study Moderate severe reaction contrast medical history Treatment I131 course trial Use metformin Morbus Kahler Morbus Waldenstrom excretion light chain urine medical history Kidney dysfunction ( MDRDGFR &lt; 60 ml/min/1.73m2 ECC &lt; 60 ml/min , calculate CockcroftGault formula ) ; case decrease body muscle mass , exact ECC measure use serum urine creatinine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>liver cyst</keyword>
</DOC>